Targeting cancer metabolism: Dietary and pharmacologic interventions

Claudio Vernieri, Stefano Casola, Marco Foiani, Filippo Pietrantonio, Filippo de Braud, Valter Longo

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor-and patient-related characteristics. Significance: To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.

Original languageEnglish
Pages (from-to)1315-1333
Number of pages19
JournalCancer Discovery
Volume6
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Neoplasms
Metabolic Networks and Pathways
Therapeutics
Drug Delivery Systems
Growth
Oncogenes
Food
Enzymes

ASJC Scopus subject areas

  • Oncology

Cite this

Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016). Targeting cancer metabolism: Dietary and pharmacologic interventions. Cancer Discovery, 6(12), 1315-1333. https://doi.org/10.1158/2159-8290.CD-16-0615

Targeting cancer metabolism : Dietary and pharmacologic interventions. / Vernieri, Claudio; Casola, Stefano; Foiani, Marco; Pietrantonio, Filippo; de Braud, Filippo; Longo, Valter.

In: Cancer Discovery, Vol. 6, No. 12, 01.12.2016, p. 1315-1333.

Research output: Contribution to journalReview article

Vernieri, C, Casola, S, Foiani, M, Pietrantonio, F, de Braud, F & Longo, V 2016, 'Targeting cancer metabolism: Dietary and pharmacologic interventions', Cancer Discovery, vol. 6, no. 12, pp. 1315-1333. https://doi.org/10.1158/2159-8290.CD-16-0615
Vernieri, Claudio ; Casola, Stefano ; Foiani, Marco ; Pietrantonio, Filippo ; de Braud, Filippo ; Longo, Valter. / Targeting cancer metabolism : Dietary and pharmacologic interventions. In: Cancer Discovery. 2016 ; Vol. 6, No. 12. pp. 1315-1333.
@article{7b41177c92004af9bc550fbf608cf832,
title = "Targeting cancer metabolism: Dietary and pharmacologic interventions",
abstract = "Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor-and patient-related characteristics. Significance: To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.",
author = "Claudio Vernieri and Stefano Casola and Marco Foiani and Filippo Pietrantonio and {de Braud}, Filippo and Valter Longo",
year = "2016",
month = "12",
day = "1",
doi = "10.1158/2159-8290.CD-16-0615",
language = "English",
volume = "6",
pages = "1315--1333",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Targeting cancer metabolism

T2 - Dietary and pharmacologic interventions

AU - Vernieri, Claudio

AU - Casola, Stefano

AU - Foiani, Marco

AU - Pietrantonio, Filippo

AU - de Braud, Filippo

AU - Longo, Valter

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor-and patient-related characteristics. Significance: To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.

AB - Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor-and patient-related characteristics. Significance: To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.

UR - http://www.scopus.com/inward/record.url?scp=85007329790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007329790&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-0615

DO - 10.1158/2159-8290.CD-16-0615

M3 - Review article

AN - SCOPUS:85007329790

VL - 6

SP - 1315

EP - 1333

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 12

ER -